The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2014Defining the Contribution of Neuroinflammation to Parkinson's Disease
Study Rationale:
Over-activation of brain immune cells, called microglia, is associated with the degeneration that occurs in Parkinson’s disease. This suggests that brain... -
Therapeutic Pipeline Program, 2014Augmenting Treatment Effects of Voice Therapy in Parkinson’s Disease
Study Rationale:
Speech and voice disorders are common in people with Parkinson’s disease (PD) and adversely affect their communication and quality of life. Presently, Lee Silverman... -
Improved Biomarkers and Clinical Outcome Measures, 2019Correlating MRI, Pathology and Cognitive Assessments toward Biomarkers of Cognitive Decline
Study Rationale:
Parkinson’s studies are working to identify magnetic resonance imaging (MRI) biomarkers for early diagnosis, disease severity and progression. However, attempts to explore how brain... -
Improved Biomarkers and Clinical Outcome Measures, 2019International Validation of Two Non-motor Symptom Scales in Parkinson’s Disease
Study Rationale:
Non-motor Parkinson’s symptoms can fluctuate with dopaminergic medication effectiveness. Anxiety, sadness, lack of energy and fatigue are common symptoms during the off-medication... -
Target Advancement Program, 2019Identifying Protein Sequence of Potential Drug Target Synuclein Nitrase
Study Rationale:
We have found that alpha-synuclein nitration and aggregation — which may play a role in Parkinson’s disease — is catalyzed by an enzyme that we have termed synuclein nitrase. In this... -
Target Advancement Program, 2019Chaperone-mediated Autophagy to Counteract Alpha-synuclein Pathology
Study Rationale:
A hallmark of Parkinson’s disease (PD) is aggregates of the protein alpha-synuclein. One of the main pathways to remove excess amounts of alpha-synuclein, which can be toxic for the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.